Skip to content

Insight

From aptamer to Optimer

Why we do this. What the benefit is for you. Aptamers are increasingly being used across the life sciences in research, diagnostics and therapeutics. We have years of experience in…

Speeding the time-to-clinic with Optimer®

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

Oligo therapeutics vs ADCs. How do they stack up?

  Biologics, such as antibody therapeutics have revolutionised our approach to the treatment of disease. Therapeutic antibodies have become the predominant class of drugs in the development pipeline and the…

Expanding proteomic capabilities with Optimers

The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…

How robust are Optimer-based affinity columns?

As part of the Biologics Europe digital conference our CTO, Dr David Bunka, was invited to present as part of Sartorius’ workshop in the ‘Protein Engineering, Protein & Antibody…

Aptamer-enhanced gene therapy delivery

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…